Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
The Influence of a rapid relief of gastro esophageal reflux disease (GERD) symptoms on the quality of life and patient satisfaction after initiating treatment with a Proton Pump Inhibitor.	Sanofi	Ongoing	N/A	4	DRIEG_L_05705	University District Hospital (Jeddah)
Venous Thromboembolic Risk Assessment of Post-Partum Females in Saudi Arabia Utilizing Royal College of Obstetrics and Gynecology Risk Assessment Model	Sanofi	Ongoing	N/A	4	DIREG_L_06410	King Abdulaziz University Hospital (Jeddah)
An observational registry improving Control of Hypertension and Achieving Normalization Goal Earlier	Sanofi	Ongoing	N/A	4	DIREG_L_05059	Erfan & Bagedo General Hospital (Jeddah)
International Diabetes Management Practices Study (Wave 5)	Sanofi	Ongoing	N/A	4	DIREG_R_05941	King Fahad Hospital (Jeddah)
An observational study to monitor the efficacy and tolerability of levofloxacin 250 mg OD for treatment of simple lower UTI in Saudi Arabia	Sanofi	Ongoing	Levofloxacin	4	LEVOF_L_05172	Erfan & Bagedo General Hospital (Jeddah)
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma orOcular Hypertension.	Allergan	Ongoing	Bimatoprost SR	3	192024-092	King Khaled Eye Specialist Hospital (Riyadh), King Abdullah Medical City (Makkah)
A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).	Bayer	Completed	Riociguat	2	BAY 63-2521 / 13605	King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh)
Efficacy and Safety Assessment of NIlotinib in Chronic Myeloid Leukemia (CML) Patients with Suboptimal Response on Imatinib Therapy (NISRI)	KAIMRC	Ongoing	NILOTINIB	4	RC12/052/R	King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam)
Tracking Biologics Along the Silk Road	Janssen-Cilag International NV	Ongoing	Infliximab / Golimumab / Ustekinumab	4	C0168ARA40	King Khalid University Hospital (Riyadh)
A study of the factors predicting radiation exposure to contacts of Saudi patients treated with radioactive iodine (I 131): A preliminary study for patients’ criteria selection for possible high dose I131 therapy on out-patient basis in the future	King Abdulaziz City for Science and Technology (KACST)	Completed	131 Iodine	4	(version#1) dated 10-Apr-14	King Abdullah Medical City (Makkah)